Literature DB >> 29182193

[Microarrays in 236 patients with neurodevelopmental disorders and congenital abnormalities].

Víctor Faundes1, Lorena Santa María1, Paulina Morales1, Bianca Curotto1, María Angélica Alliende1.   

Abstract

BACKGROUND: In 20% of neurodevelopmental disorders (NDD) and congenital abnormalities (CA) the cause would be a genomic imbalance detectable only by chromosomal microarrays (CMA). AIM: To analyze the results of CMA performed at the INTA Laboratory of Molecular Cytogenetics, during a period of four years in patients with NDD or CA.
MATERIAL AND METHODS: Retrospective study that included all CMA reports of Chilean patients. Age, sex, clinical diagnosis and origin were analyzed, as well as the characteristics of the finding. The percentage of cases diagnosed by CMA was calculated considering all patients with pathogenic (PV) or probably pathogenic variants (VLP). Finally, we studied the association between patients' characteristics and a positive CMA outcome.
RESULTS: A total of 236 reports were analyzed. The median age was 5.41 (range 2.25-9.33) years, and 59% were men. Ninety chromosomal imbalances were found, which corresponded mainly to deletions (53.3%), with a median size of 1.662 (range 0.553-6.673) Megabases. The diagnostic rate of CMA in Chilean patients from all over the country was 19.2%. There was a close relationship between the patient's sex and the detection of VLP/VP (p = 0.034).
CONCLUSIONS: Our diagnostic rate and the association between female sex and a higher percentage of diagnosed cases are concordant with other international studies. Therefore, CMA is a valid diagnostic tool in the Chilean population.

Entities:  

Mesh:

Year:  2017        PMID: 29182193     DOI: 10.4067/s0034-98872017000700854

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  1 in total

1.  Counteracting epigenetic mechanisms regulate the structural development of neuronal circuitry in human neurons.

Authors:  Seonhye Cheon; Allison M Culver; Anna M Bagnell; Foster D Ritchie; Janay M Vacharasin; Mikayla M McCord; Carin M Papendorp; Evelyn Chukwurah; Austin J Smith; Mara H Cowen; Trevor A Moreland; Pankaj S Ghate; Shannon W Davis; Judy S Liu; Sofia B Lizarraga
Journal:  Mol Psychiatry       Date:  2022-02-24       Impact factor: 13.437

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.